Synergistic anticancer effects of ABT-199 and Vorinostat encapsulated in PLGA nanoparticles: Formulation, characterization, and antiproliferative effects against colorectal cancer cells
Fig 5
Drug release kinetics of ABT-199 (A) and Vorinostat (B).
A total amount of 10 mg of each NP formulation was re-suspended in 3 ml of PBS and injected in a dialysis bag which was then immersed in a PBS containing 10% FBS. At the indicated time points, the remaining NP pellet was removed and quantified. Data represent mean ± Standard Error of the Mean (SEM).